Fermenta Biotech Ltd

- The company is being cautious about over-leveraging and does not plan to significantly increase debt for upcoming CAPEX requirements, particularly for the Saykha project. - For certain new products like pre-mixes, the company has already taken additional debt, increasing it by about Rs. 25 to 30 crores for the Kullu project. - No anticipated CAPEX-related debt is expected for new products like Vitamin K1 and vegan D3 as they will utilize existing multi-purpose plants. - The company is monetizing land assets (e.g., Thane, Pune) to fund investments, aiming to avoid increasing debt levels. - No specific mention of equity fundraising was indicated in the transcript.

- Saykha Project: Estimated total investment of Rs. 150 to Rs. 200 crores to be done in phases; currently delayed due to resource availability and strategic decisions (Page 13). - Pre-mix Plant: Initiated as a brownfield project in Kullu; plant expected to be commissioned and commercialized by Q4 FY22 (Page 8 and 13). - Multi-purpose Plant Expansion at Dahej: Capacity expansion completed; supports Vitamin D3 and upcoming products like K1 and vegan D3 without additional CAPEX for these products (Page 10 and 14). - Cautious approach on new CAPEX to avoid over-leveraging; preference to monetize land assets (Page 12, 13). - Thane Land: Developing through joint venture Mextech Properties, monetizing via development rights without upfront capital expenditure (Page 12). - No anticipated CAPEX for new products like K1 and vegan D3 initially, leveraging existing Dahej plant capacity (Page 13). - Debt increased by Rs. 25-30 crores for Kullu pre-mix plant; no significant additional debt planned currently (Page 12).

- The company expects about a 20%-25% increase in volumes from capacity expansions, particularly if fully utilized for Vitamin D3, which can significantly boost revenue. - New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next two quarters, which could further drive growth. - The Saykha plant’s implementation is delayed but will provide additional capacity for new products and minerals, supporting future volume growth. - The human nutrition segment has grown steadily, with a focus on expanding market share, indicating potential revenue increases in this segment. - Animal feed volumes and prices have been volatile and suppressed; a recovery could lead to improved margins and higher revenues, but this remains uncertain. - The management refrains from giving specific volume guidance due to market volatility but remains confident in achieving an average EBITDA margin of around 20% over 4-5 years, reflecting steady operational growth.

- The company targets an average EBITDA margin of around 20% over the next 4-5 years; current margins are volatile mainly due to animal feed segment fluctuations. - If animal feed prices improve, margins could increase to 23-25% or even higher, as historically margins reached up to 37%. - Volume guidance is not publicly given due to prudence, but capacity expansions could lead to a 20-25% increase in Vitamin D3 volumes, supporting revenue growth. - New product launches like vegan Vitamin D3 and Vitamin K1 are expected within 1-2 quarters, potentially driving future revenue. - Capital expenditure is cautiously planned to avoid over-leverage; some debt (~Rs. 25-30 crores) has been taken for premix plant expansion. - Real estate monetization is underway to support funding without increasing debt significantly. - Overall, the company remains confident about steady earnings growth and profitability improvements in the medium term.

The transcript does not provide explicit details about the current or expected order book or pending orders for Fermenta Biotech Limited. However, relevant insights include: - Q4 FY22 showed increased volumes in human Vitamin D3 (15% growth quarter-on-quarter) and decreased animal feed volumes (64% decline quarter-on-quarter), indicating ongoing demand dynamics. - The company has focused on catering to the increased Vitamin D3 human nutrition demand during the COVID period. - New product launches like vegan Vitamin D3 and Vitamin K1 are targeted within the next 2 quarters, potentially contributing to future orders. - The onboarding of new customers in the human nutrition segment suggests a growing order pipeline. - The German and US subsidiaries are gaining approvals and customers which will aid in increasing volumes and order inflow. - Pre-mixes plant in Kullu expected to be commercialized by Q4 FY22, indicating forthcoming order fulfillment capability. - No specific figures or direct commentary on the exact order book or backlog are mentioned.